Back to Journals » Cancer Management and Research » Volume 13
Columbamine-Mediated PTEN/AKT Signal Pathway Regulates the Progression of Glioma [Retraction]
Niu HT, Liu Y, Wang YZ, Tian Y, Yang M, Jiang HS. Cancer Manag Res. 2021;13:489–497.
The Editor-in-chief and Publisher of Cancer Management and Research wish to retract the published article. Concerns were raised of alleged image duplication with images found in other publications for unrelated studies. Specifically:
- Figure 1B, SHG44 panel, Columbamine 50 µM, appears to have been duplicated with an image from Figure 2B panel CDDP/CQ-PLA NPs published in Li et al, 2021 (https://doi.org/10.18632/aging.202297).
- Figure 6A, Control tumor image, far right, appears to have been duplicated with an image from Figure 7A, LINC00662 vector tumor image, right, which has been rotated, published in Lv et al, 2021 (https://doi.org/10.18632/aging.202522).
- Figure 6A, Columbamine tumor images, right, appear to have been duplicated with images from Figure 3A, TCCSUP tumor images, right, which have been flipped, published in Dong et al, 2021 (https://doi.org/10.3389/fcell.2021.650999).
Despite several attempts, the author could not be contacted for an explanation and the decision was made to retract the article.
Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.